KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Goodwill & Intangibles (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Goodwill & Intangibles for 4 consecutive years, with $924.6 million as the latest value for Q4 2025.

  • Quarterly Goodwill & Intangibles changed N/A to $924.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $924.6 million through Dec 2025, changed N/A year-over-year, with the annual reading at $924.6 million for FY2025, N/A changed from the prior year.
  • Goodwill & Intangibles hit $924.6 million in Q4 2025 for Royalty Pharma, roughly flat from $924.6 million in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $924.6 million in Q2 2025 to a low of $5.7 million in Q4 2021.